Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Combo Product Filer Can Contact FDA If First Action Date Missed – Guidance

Executive Summary

For a combination product being reviewed under two separate applications, the sponsor can file a dispute resolution request to the Office of Combination Products once the first of the two action dates has passed

You may also be interested in...

Combination Product Review Assignment Should Consider Precedent – Abbott

FDA's combination product review rule should take precedent into account in assigning drug and diagnostic products used together, Abbott says

Combo Product Primary Mode Of Action, Dispute Resolution Detailed By FDA

Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns under a proposed rule

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts